# Petros Pharmaceuticals, Inc.

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/fi/companies/Petros Pharmaceuticals, Inc.).

## Overview

Petros Pharmaceuticals, Inc. is a U.S.-based pharmaceutical company organized around prescription erectile dysfunction products and related men’s health devices. The company has operated through subsidiaries including Metuchen Pharmaceuticals, Timm Medical Technologies, and Pos-T-Vac, with activities historically centered on Stendra® and vacuum erection devices.

## Products & services

• Stendra® prescription erectile dysfunction treatment
• Vacuum erection devices (VEDs)
• Osbon ErecAid VED products
• Pos-T-Vac VED products
• OTC and ACNU self-care product development

- **Prescription ED Pharmaceuticals** (60%) — Prescription erectile dysfunction therapy historically commercialized under the Stendra® brand.
- **Vacuum Erection Devices** (35%) — Mechanical erectile dysfunction devices sold through Timm Medical and Pos-T-Vac.
- **Self-Care OTC / ACNU Development** (5%) — Development efforts aimed at nonprescription pharmaceutical products and ACNU treatments.

- Stendra® prescription erectile dysfunction treatment
- Vacuum erection devices (VEDs)
- Osbon ErecAid VED products
- Pos-T-Vac VED products
- OTC and ACNU self-care product development

## Customers

The company’s historical customers include adult men seeking treatment for erectile dysfunction through prescription or device-based options. Its products have also been sold through wholesalers, retailers, and other distribution channels that serve pharmacies and men’s health markets. The emerging self-care focus is aimed at consumers and channel partners that support nonprescription access to selected pharmaceutical products.

- **ED patients** (primary) — Men seeking prescription or device-based erectile dysfunction treatment.
- **Wholesalers and distributors** (primary) — Buy and distribute Stendra® and related pharmaceutical products through commercial channels.
- **Retail/device channels** (secondary) — Purchase VED products for resale to men’s health consumers.
- **OTC/self-care consumers** (emerging) — Future target users for nonprescription pharmaceutical products and ACNU offerings.

- Adult men seeking treatment for erectile dysfunction
- Wholesalers and distributors of prescription pharmaceuticals
- Retailers and channel partners for men’s health devices
- Consumers seeking nonprescription self-care options
- Partners supporting OTC and ACNU product access

## Geography

Petros is a U.S.-based company with operations and commercial activity historically centered in the United States. Its products have been marketed in U.S. pharmaceutical and device channels, and the company’s corporate structure is organized through Delaware-based parent and operating subsidiaries.

- **United States** (100%) — No country-level revenue disclosure provided in the excerpts; business is U.S.-focused.

- Headquartered in the United States
- Commercial activity historically centered in U.S. markets
- Subsidiaries support pharmaceutical and device operations
- Distribution has relied on U.S. wholesale and retail channels

## Strategy

Petros is repositioning its business toward nonprescription pharmaceuticals and ACNU products while evaluating internal development, collaborations, and acquisitions. The strategy depends on securing capital and external partners to build a new commercial platform after the historical ED and device businesses were discontinued or assigned away.

- **Build a nonprescription product platform** (medium-term) — The company is trying to replace legacy ED revenue with self-care products that can be commercialized through broader consumer channels.
- **Pursue collaborations and acquisitions** (medium-term) — External deals can add products, rights, or capabilities faster than internal development alone.
- **Secure financing** (short-term) — Development and commercialization require capital before new products can generate meaningful revenue.

- Shift toward OTC and ACNU self-care products
- Use internal development and collaborations to build pipeline
- Evaluate asset acquisitions and business combinations
- Seek financing to support development and commercialization

## Risks

Petros faces substantial going-concern and financing risk because it has limited operating resources and depends on external capital to fund development and commercialization. The business also carries execution risk from its transition away from legacy products, plus market and regulatory risk inherent in pharmaceutical development, OTC conversion, and distribution.

- **Going concern uncertainty** [critical] — The company has reported negative operating cash flow and limited cash resources, creating doubt about its ability to fund operations.
- **Need for additional capital** [high] — Development and commercialization require funding before new products can generate cash flow.
- **Transition away from legacy revenue streams** [high] — Historical ED and device businesses were discontinued or assigned, removing established revenue sources.
- **OTC market liquidity and delisting risk** [medium] — Trading on OTC markets can reduce liquidity and investor access compared with a national exchange.
- **Regulatory and commercialization risk** [high] — OTC/nonprescription pharmaceutical products require regulatory clearance and market acceptance.

- Going-concern risk and dependence on new financing
- Execution risk from replacing discontinued legacy products
- Regulatory risk for OTC and ACNU product pathways
- Commercial risk if new products fail to gain distribution
- Listing and liquidity risk from OTC trading status

## Accounting

Investors should watch how Petros accounts for discontinued operations, asset assignments, and any gains or losses tied to settlements and disposals. The company also relies on significant estimates for income taxes, litigation, contingencies, and going-concern disclosures, all of which can materially affect reported results and balance-sheet presentation.

- **Discontinued operations** — Affects comparability of current-period results
- **Going concern assessment** — Influences disclosure and asset/liability presentation
- **Contingencies and litigation estimates** — May affect reserves and expense recognition
- **Settlement accounting** — Can create one-time gains or balance-sheet reclassifications

- Discontinued operations presentation affects comparability
- Settlement and disposal gains/losses can distort period results
- Going-concern disclosures reflect liquidity assumptions
- Estimates for taxes, litigation, and contingencies are judgmental

---

*Last updated: 2026-04-29T04:48:31.706745+00:00*